Adjuvant chemotherapy for breast cancer

J. F. Holland

Research output: Contribution to journalArticlepeer-review

Abstract

Patients of the 1980s with breast cancer have better prospects of disease-free survival than has hitherto been the case because of the availability of effective chemotherapy given adjuvantly. Women at the highest risk have had the most dramatic relative benefits. (CMFVP) is superior to CMF and to L-PAM in women with four or more nodes at all ages. CMFVP is superior to PFT and to P(A)F in premenopausal women, and equal to PFT in postmenopausal women with four or more nodes. PFT is better than P(A)F in postmenopausal women. FAC appears equal to CMFVP, but with an unknown risk of later cardiac damage. Adjuvant chemotherapy improves the surgical outcome of women with breast cancer. C=cyclophosphamide M=methotrexate F=5-fluorouracil V=vincristine P=prednisone L-PAM=L-phenylalanine mustard T=tamoxifen A=adriamycine P(A)=L-PAM.

Original languageEnglish
Pages (from-to)1361-1370
Number of pages10
JournalSurgical Clinics of North America
Volume61
Issue number6
DOIs
StatePublished - 1981

Cite this